Canine Nephrotic Syndrome: Diagnosis and Management

Nephrotic syndrome in dogs is a clinical entity defined by the triad of marked proteinuria, hypoalbuminemia, and edema or effusions, resulting from glomerular disease. This article provides veterinarians with a systematic approach to diagnosing and managing this condition, focusing on evidence-based diagnostic workup, therapeutic options including ACE inhibitors and immunosuppression, dietary modification, and anticoagulation strategies. The content is grounded in peer-reviewed literature and authoritative veterinary resources, with clear escalation criteria for specialist referral.

At a Glance

Pathophysiology of Nephrotic Syndrome in Dogs

Nephrotic syndrome arises from glomerular injury that increases permeability to proteins, particularly albumin. The glomerular filtration barrier consists of fenestrated endothelium, glomerular basement membrane, and podocyte foot processes with slit diaphragms. Damage to any component can lead to proteinuria. In dogs, common underlying causes include membranous glomerulonephritis, membranoproliferative glomerulonephritis, minimal change disease, and renal amyloidosis. The Merck Veterinary Manual provides an overview of glomerular diseases in dogs, noting that immune complex deposition is a frequent mechanism. Podocyte injury is central to proteinuria development, as demonstrated in experimental models where activation of the angiotensin II-TRPC6 pathway induces podocyte damage and contributes to proteinuria in nephrotic syndrome. This pathway is a target for angiotensin receptor blockers like losartan, which are used in human nephrotic syndrome management.

The loss of albumin into urine leads to hypoalbuminemia, which reduces plasma oncotic pressure. This shift of fluid from the vascular space to the interstitium causes edema and effusions. Hypoalbuminemia also disrupts the balance of thrombotic and antithrombotic factors, predisposing dogs to thromboembolic complications. A case report documented nephrotic syndrome resulting in thromboembolic disease and disseminated intravascular coagulation in a dog, highlighting the severity of this complication. The degree of hypoalbuminemia and severity of proteinuria are predictors of thromboembolic risk, as described in human nephrotic syndrome literature.

Diagnostic Workup for Canine Nephrotic Syndrome

A systematic diagnostic approach is essential to confirm nephrotic syndrome, identify the underlying glomerular disease, and assess for complications. The workup should include urinalysis, urine protein:creatinine ratio (UPC), serum biochemistry, complete blood count, blood pressure measurement, infectious disease screening, and renal biopsy when indicated.

Urinalysis and Urine Protein:Creatinine Ratio

Persistent proteinuria is the hallmark of nephrotic syndrome. A urinalysis should be performed to detect proteinuria and evaluate for sediment abnormalities such as casts or red blood cells. The UPC ratio quantifies proteinuria and is more accurate than dipstick alone. A UPC greater than 2.0 is typical in nephrotic syndrome, though values can exceed 10.0. The UPC should be measured on a voided or catheterized sample, ideally from a morning collection. Serial UPC measurements are used to monitor response to therapy. Prerenal (e.g., hemoglobinuria, myoglobinuria) and post-renal (e.g., urinary tract infection, hemorrhage) causes of proteinuria must be excluded before attributing proteinuria to glomerular disease.

Serum Biochemistry and Albumin Measurement

Serum albumin is a key diagnostic criterion. Hypoalbuminemia is defined as serum albumin below the reference interval, typically less than 2.0 g/dL. In nephrotic syndrome, albumin loss is primarily renal, but concurrent hepatic disease or protein-losing enteropathy should be considered if albumin is disproportionately low relative to proteinuria. Serum creatinine and blood urea nitrogen assess renal function. Hypercholesterolemia is common due to increased hepatic lipoprotein synthesis. Electrolytes, including sodium and potassium, should be monitored, especially if diuretics are used.

Blood Pressure Assessment

Systemic hypertension is a frequent complication of glomerular disease and can worsen proteinuria and renal injury. Blood pressure should be measured using Doppler or oscillometric methods, with the dog in a calm state. Multiple readings are recommended. Hypertension is defined as systolic pressure greater than 160 mmHg or diastolic pressure greater than 100 mmHg. Management of hypertension is integral to reducing proteinuria and slowing disease progression.

Infectious Disease Screening

Secondary glomerulonephritis can result from chronic infections such as ehrlichiosis, leishmaniasis, babesiosis, heartworm disease, and bacterial endocarditis. Screening for these infections is indicated, especially in endemic areas. Serology for Ehrlichia canis, Anaplasma spp., Borrelia burgdorferi, and Leishmania infantum should be considered. Heartworm antigen testing and microfilaria examination are also recommended. If an infectious cause is identified, treatment of the underlying infection may lead to resolution of proteinuria.

Renal Biopsy

Renal biopsy is the gold standard for definitive diagnosis of the underlying glomerular pathology. It is indicated when the cause of nephrotic syndrome is unclear, when immunosuppressive therapy is being considered, or when disease progression is rapid. Biopsy can differentiate between glomerulonephritis, amyloidosis, and other glomerular diseases. The procedure should be performed by a specialist using ultrasound guidance, with coagulation parameters assessed beforehand. Histopathology, immunofluorescence, and electron microscopy provide the most complete evaluation. The Merck Veterinary Manual notes that biopsy is essential for guiding therapy and prognosis. However, biopsy carries risks including hemorrhage and renal damage, and should only be performed when the results will alter management.

Management of Nephrotic Syndrome in Dogs

Management of nephrotic syndrome targets reducing proteinuria, controlling hypertension, managing edema, preventing thromboembolism, and treating the underlying glomerular disease. A multimodal approach is often required, with therapy tailored to the individual dog based on diagnostic findings and disease severity.

ACE Inhibitors and Angiotensin Receptor Blockers

Angiotensin-converting enzyme (ACE) inhibitors are first-line antiproteinuric therapy in dogs with glomerular disease. Benazepril and enalapril reduce proteinuria by decreasing glomerular capillary pressure and attenuating angiotensin II-mediated podocyte injury. An algorithm for administering ACE inhibitors and ARBs to treat proteinuria in dogs with glomerular disease provides a structured approach to dosing and monitoring. Treatment of X-linked hereditary nephritis in Samoyed dogs with an ACE inhibitor demonstrated renoprotective effects, supporting the use of these drugs in hereditary glomerular disease. Plasma concentrations of benazepril and its active metabolite benazeprilat have been studied in dogs with experimental kidney impairment, confirming drug accumulation in renal disease. ACE inhibitors should be started at a low dose and titrated based on UPC response and renal function. Serum creatinine and potassium should be monitored within one to two weeks of initiation or dose change. Angiotensin receptor blockers (ARBs) such as telmisartan are alternatives if ACE inhibitors are not tolerated or are ineffective. The combination of an ACE inhibitor and ARB may provide additional antiproteinuric benefit but requires close monitoring for hyperkalemia and azotemia.

Immunosuppressive Therapy

Immunosuppression is indicated for immune-mediated glomerulonephritis, typically confirmed by renal biopsy. Glucocorticoids (prednisolone) are used in minimal change disease and some forms of membranous glomerulonephritis. However, glucocorticoids can worsen proteinuria in dogs with glomerular disease and should be used cautiously. Cyclosporine, mycophenolate mofetil, and azathioprine are alternative or adjunctive immunosuppressants. A case report described combination of immunosuppressive drugs and allogeneic stem cell treatment in a dog with suspected nephrotic syndrome, suggesting potential for novel therapies. Immunosuppressive therapy should be managed by a veterinary internist or nephrologist, with regular monitoring of UPC, renal function, and drug levels. Response to therapy is variable, and some dogs may require long-term treatment.

Dietary Modification

Dietary management is a cornerstone of nephrotic syndrome treatment. A renal protective diet is recommended, characterized by reduced protein content (to decrease proteinuria and uremic toxin production), restricted phosphorus (to slow renal disease progression), and low sodium (to control hypertension and edema). Omega-3 fatty acid supplementation may have anti-inflammatory and antiproteinuric effects. Caloric intake should be adequate to maintain body weight, as hypoalbuminemia can lead to muscle wasting. Commercial renal diets are available and should be introduced gradually. Homemade diets formulated by a veterinary nutritionist are an option for dogs with food sensitivities or poor acceptance of commercial diets.

Edema Management

Edema and effusions result from hypoalbuminemia and sodium retention. Dietary sodium restriction is the first step. If edema is severe or causing respiratory compromise, diuretics such as furosemide may be used cautiously. Loop diuretics can worsen prerenal azotemia and electrolyte disturbances. Spironolactone, a potassium-sparing diuretic, may be preferred but is less potent. Diuretic therapy should be monitored with body weight, urine output, and serum electrolytes. In refractory cases, colloid therapy (e.g., hetastarch) may be considered, but hetastarch has been associated with renal injury in critically ill dogs and should be used with caution. The goal is to manage edema without compromising renal perfusion.

Anticoagulation for Thromboembolic Risk

Thromboembolism is a life-threatening complication of nephrotic syndrome. The pathophysiology involves loss of antithrombin III in urine, increased platelet aggregation, and altered fibrinolysis. A case report documented nephrotic syndrome resulting in thromboembolic disease and disseminated intravascular coagulation in a dog. The degree of hypoalbuminemia and severity of proteinuria are predictors of risk. Prophylactic anticoagulation should be considered in dogs with serum albumin less than 1.5 g/dL or a history of thromboembolism. Low-dose aspirin may be used for platelet inhibition, though evidence in dogs is limited. Clopidogrel is an alternative. For dogs with confirmed thromboembolism, heparin (unfractionated or low molecular weight) followed by warfarin may be indicated, but this requires intensive monitoring and specialist consultation. The duration of anticoagulation depends on resolution of hypoalbuminemia and risk factors.

Monitoring and Follow-Up

Regular monitoring is essential to assess response to therapy, detect complications, and adjust treatment. The frequency of rechecks depends on disease severity and stability.

Urine Protein:Creatinine Ratio

Serial UPC measurements are the primary indicator of antiproteinuric efficacy. A target UPC less than 1.0 is ideal, but a 50% reduction from baseline is considered a positive response. UPC should be measured at each recheck, typically every one to three months. If UPC increases, the underlying cause should be investigated, including progression of glomerular disease, development of hypertension, or noncompliance with therapy.

Serum Albumin and Renal Function

Serum albumin should be monitored to assess resolution of hypoalbuminemia. An increase toward the reference interval indicates effective management. Serum creatinine and blood urea nitrogen track renal function. Worsening azotemia may indicate disease progression, dehydration, or adverse effects of therapy (e.g., ACE inhibitors, diuretics). Electrolytes, particularly potassium, should be monitored with ACE inhibitor or ARB therapy.

Blood Pressure

Blood pressure should be measured at each recheck. Persistent hypertension requires adjustment of antihypertensive therapy. Target systolic pressure is less than 160 mmHg. If hypertension is uncontrolled, additional agents such as amlodipine may be added.

Body Weight and Edema

Body weight and physical examination for edema or effusions should be performed at each visit. Weight gain may indicate fluid retention, while weight loss may reflect muscle wasting or dehydration. Diuretic therapy should be adjusted based on edema status and renal function.

Common Failure Patterns

Several factors can lead to suboptimal outcomes in managing nephrotic syndrome. Recognizing these patterns allows for timely intervention.

Inadequate Antiproteinuric Response

Failure to achieve a significant reduction in UPC may result from insufficient ACE inhibitor or ARB dosing, noncompliance, or progression of glomerular disease. If UPC does not decrease by at least 50% within two to three months, consider increasing the dose, adding an ARB, or switching to an alternative ACE inhibitor. Concurrent hypertension should be controlled. If proteinuria persists despite maximal medical therapy, renal biopsy may be indicated to guide immunosuppressive therapy.

Worsening Azotemia

ACE inhibitors and ARBs can cause acute kidney injury, particularly in dogs with preexisting renal disease or volume depletion. If serum creatinine increases by more than 30% within one to two weeks of starting therapy, the drug should be temporarily discontinued and volume status assessed. Once volume replete, the drug can be restarted at a lower dose. Persistent azotemia may indicate disease progression.

Thromboembolic Events

Despite prophylactic anticoagulation, thromboembolism can occur. Clinical signs include acute dyspnea (pulmonary thromboembolism), hindlimb paresis (aortic thromboembolism), or neurologic deficits (cerebral thromboembolism). Immediate veterinary emergency care is required. Dogs with a history of thromboembolism should be on long-term anticoagulation with close monitoring.

Recurrent Edema

Edema may recur if dietary sodium restriction is not maintained or if diuretic therapy is inadequate. Noncompliance with a low-sodium diet is a common cause. If edema is refractory, consider adding a second diuretic (e.g., spironolactone) or increasing the dose of the current diuretic. However, aggressive diuresis can worsen azotemia and electrolyte disturbances.

Limitations and Professional Escalation Criteria

Management of nephrotic syndrome has limitations. Not all dogs respond to ACE inhibitors or immunosuppression. Renal biopsy is not always feasible due to cost, risk, or lack of specialist access. Prognosis varies widely depending on the underlying glomerular disease and response to therapy. Dogs with amyloidosis generally have a poorer prognosis than those with minimal change disease.

Veterinarians should consider referral to a veterinary internist or nephrologist in the following situations:

• Diagnostic uncertainty after initial workup
• Failure to achieve a 50% reduction in UPC after three months of ACE inhibitor therapy
• Progressive azotemia despite medical management
• Severe or recurrent thromboembolism
• Need for renal biopsy or immunosuppressive therapy
• Uncontrolled hypertension despite multiple antihypertensive agents
• Development of end-stage renal disease requiring dialysis or transplantation

The World Organisation for Animal Health provides guidelines for animal health and welfare, which include standards for veterinary care and disease management. Adherence to these standards ensures ethical and effective treatment.

Practical Decision Framework for Antiproteinuric Therapy Titration and Monitoring in Canine Nephrotic Syndrome

Managing antiproteinuric therapy in dogs with nephrotic syndrome requires a structured, evidence-based approach that balances efficacy with renal safety. The following framework provides veterinarians with a stepwise protocol for initiating, titrating, and monitoring ACE inhibitor and angiotensin receptor blocker therapy, incorporating specific decision points, record-keeping requirements, and escalation criteria. This framework complements the general management principles described above by offering concrete operational guidance for daily clinical practice.

Initial Patient Assessment and Baseline Data Collection

Before initiating antiproteinuric therapy, a complete baseline assessment is essential. The minimum database should include serum creatinine, blood urea nitrogen, serum albumin, serum potassium, systolic blood pressure, and urine protein:creatinine ratio. The Merck Veterinary Manual emphasizes that accurate baseline values are critical for monitoring therapeutic response and detecting adverse effects. Baseline UPC should be measured on at least two separate occasions, ideally one to two weeks apart, to confirm persistent proteinuria and establish a reliable pretreatment value. If the UPC varies by more than 30% between measurements, a third sample should be obtained before starting therapy.

Volume status must be assessed clinically. Dogs with dehydration, hypovolemia, or concurrent diuretic therapy are at increased risk of acute kidney injury when ACE inhibitors are initiated. If the dog is receiving diuretics for edema management, the diuretic dose should be stabilized for at least three to five days before starting an ACE inhibitor. Serum creatinine should be stable or improving before initiating therapy. If the dog is azotemic, the underlying cause should be identified and addressed before starting an ACE inhibitor.

ACE Inhibitor Initiation Protocol

Benazepril and enalapril are the most commonly used ACE inhibitors in dogs with glomerular disease. An algorithm for administering ACE inhibitors and ARBs to treat proteinuria in dogs with glomerular disease provides a structured approach to dosing and monitoring. The starting dose for benazepril is 0.25 to 0.5 mg/kg orally every 24 hours. For enalapril, the starting dose is 0.25 to 0.5 mg/kg orally every 12 to 24 hours. Lower starting doses are recommended for dogs with baseline serum creatinine greater than 2.0 mg/dL or systolic blood pressure less than 120 mmHg.

The drug should be administered at the same time each day, with or without food. Owners should be instructed to observe for signs of weakness, lethargy, vomiting, or decreased appetite, which may indicate hypotension or azotemia. A medication log should be maintained, recording the date, dose, time of administration, and any observed adverse effects.

First Recheck Assessment: One to Two Weeks

The first recheck should occur seven to fourteen days after initiating therapy. This visit is critical for detecting acute adverse effects and establishing the initial therapeutic response. The following parameters should be measured:

• Serum creatinine and blood urea nitrogen
• Serum potassium
• Systolic blood pressure
• Urine protein:creatinine ratio
• Body weight
• Physical examination for edema or effusions

An acceptable response is defined as a UPC reduction of at least 25% from baseline without a significant increase in serum creatinine. A significant increase in serum creatinine is defined as a rise of more than 30% from baseline or an absolute value exceeding 2.5 mg/dL. If serum creatinine increases by more than 30%, the ACE inhibitor should be temporarily discontinued and volume status assessed. Once the dog is volume replete, the drug can be restarted at 50% of the original dose and rechecked again in seven days.

If serum potassium exceeds 5.5 mEq/L, the ACE inhibitor should be discontinued and serum potassium rechecked in three to five days. Persistent hyperkalemia may require dose reduction or switching to an ARB. If systolic blood pressure falls below 100 mmHg, the ACE inhibitor should be held until blood pressure normalizes, then restarted at a lower dose.

If the UPC reduction is less than 25% and serum creatinine is stable, the ACE inhibitor dose should be increased by 50% and the dog rechecked in another seven to fourteen days. This stepwise titration continues until the target UPC reduction is achieved or the maximum recommended dose is reached.

Titration Phase: Monthly Adjustments

For dogs with an acceptable initial response, the next recheck should occur at four weeks. The goal is to achieve a UPC reduction of at least 50% from baseline, with an ideal target UPC of less than 1.0. If the UPC has not decreased by at least 50%, the ACE inhibitor dose should be increased. The maximum recommended dose for benazepril is 0.5 to 1.0 mg/kg every 24 hours, and for enalapril is 0.5 mg/kg every 12 hours.

At each titration step, serum creatinine, potassium, and blood pressure must be reassessed. If the dog develops azotemia, hyperkalemia, or hypotension at any dose, the dose should be reduced to the previous tolerated level. If the maximum dose is reached without achieving a 50% UPC reduction, consider adding an angiotensin receptor blocker such as telmisartan. Telmisartan is dosed at 1 mg/kg orally every 24 hours and can be used in combination with an ACE inhibitor. The combination requires close monitoring for hyperkalemia and azotemia, with rechecks every two weeks during the first month of combination therapy.

Maintenance Phase: Long-Term Monitoring

Once a stable dose is established and the UPC target is achieved, rechecks should occur every one to three months. Each recheck should include serum creatinine, blood urea nitrogen, serum albumin, serum potassium, systolic blood pressure, UPC, body weight, and physical examination. The frequency of monitoring depends on disease stability. Dogs with stable UPC and renal function can be monitored every three months. Dogs with fluctuating parameters or those on combination therapy should be monitored monthly.

If the UPC increases by more than 50% from the previous value or exceeds 2.0, the following should be assessed:

• Owner compliance with medication administration
• Dietary compliance, particularly sodium and protein intake
• Blood pressure control
• Development of intercurrent illness or infection
• Progression of underlying glomerular disease

If no correctable cause is identified, the ACE inhibitor dose should be increased or an ARB added. If the dog is already on maximum therapy, referral for renal biopsy and consideration of immunosuppressive therapy is indicated.

Record System for Antiproteinuric Therapy

A standardized record system is essential for tracking therapeutic response and detecting trends over time. The following template can be used for each patient:

Each row represents a single visit. The notes column should document any adverse effects, dose changes, concurrent medications, or intercurrent illnesses. This record allows the clinician to visualize the trajectory of proteinuria and renal function over time and to identify patterns such as dose-dependent azotemia or seasonal fluctuations in UPC.

Troubleshooting Common Therapeutic Challenges

Several clinical scenarios require specific troubleshooting approaches.

Scenario One: Inadequate Initial Response

If the UPC does not decrease by at least 25% after two weeks of ACE inhibitor therapy at the starting dose, the most common causes are insufficient dosing, noncompliance, or concurrent hypertension. Blood pressure should be measured. If systolic pressure exceeds 160 mmHg, antihypertensive therapy should be intensified before increasing the ACE inhibitor dose. If blood pressure is controlled, the ACE inhibitor dose should be increased by 50% and the dog rechecked in two weeks. If the dog is already on the maximum dose, an ARB should be added.

Scenario Two: Azotemia with ACE Inhibitor Initiation

A rise in serum creatinine of 10% to 30% is common and acceptable, reflecting reduced glomerular capillary pressure. However, a rise of more than 30% requires intervention. The ACE inhibitor should be held, volume status assessed, and any dehydration corrected. Once volume replete, the drug should be restarted at 50% of the original dose. If azotemia recurs at the lower dose, the dog may have significant renal artery stenosis or advanced glomerulosclerosis, and ACE inhibitor therapy may not be tolerated. In such cases, consider ARB monotherapy at a low dose or referral to a specialist.

Scenario Three: Persistent Hyperkalemia

Hyperkalemia (serum potassium greater than 5.5 mEq/L) can occur with ACE inhibitor or ARB therapy, particularly in dogs with reduced renal function. Dietary potassium restriction should be reviewed. If the dog is on a potassium-sparing diuretic such as spironolactone, this should be discontinued. If hyperkalemia persists, the ACE inhibitor dose should be reduced or the drug switched to an ARB. If hyperkalemia is severe (greater than 6.0 mEq/L) or associated with cardiac arrhythmias, the drug should be discontinued and emergency treatment initiated.

Scenario Four: Hypotension

Symptomatic hypotension (systolic blood pressure less than 100 mmHg with weakness or lethargy) requires immediate dose reduction or discontinuation. Asymptomatic hypotension (systolic pressure 100 to 110 mmHg) may be tolerated if the dog is otherwise stable. If hypotension persists at the lowest effective dose, consider switching to an ARB, which may have less effect on systemic blood pressure.

Scenario Five: Breakthrough Proteinuria

A dog that was stable on ACE inhibitor therapy may develop increasing UPC over time. This breakthrough proteinuria may indicate progression of glomerular disease, development of hypertension, or noncompliance. Blood pressure should be measured and controlled. Dietary compliance should be verified. If no correctable cause is found, the ACE inhibitor dose should be increased or an ARB added. If the dog is already on maximum therapy, renal biopsy should be considered to guide further treatment.

Comparison of ACE Inhibitor and ARB Therapy

While ACE inhibitors are first-line therapy, ARBs such as telmisartan offer an alternative for dogs that do not tolerate ACE inhibitors or have an inadequate response. The following comparison aids clinical decision-making:

The choice between an ACE inhibitor and an ARB should be based on individual patient factors, including tolerance, cost, and availability. Some dogs may benefit from combination therapy, but this requires close monitoring.

Professional Escalation Criteria for Antiproteinuric Therapy

Veterinarians should consider referral to a veterinary internist or nephrologist in the following situations related to antiproteinuric therapy:

• Failure to achieve a 50% reduction in UPC after three months of maximum ACE inhibitor and ARB combination therapy
• Progressive azotemia (serum creatinine increasing by more than 0.5 mg/dL per month) despite optimal medical management
• Recurrent or severe hyperkalemia (serum potassium greater than 6.0 mEq/L) that cannot be managed with dose adjustment
• Symptomatic hypotension requiring drug discontinuation
• Development of thromboembolic complications while on prophylactic anticoagulation
• Need for renal biopsy to guide immunosuppressive therapy
• Suspected immune-mediated glomerulonephritis that may benefit from immunosuppression

The American College of Veterinary Internal Medicine provides resources for locating board-certified veterinary internists and nephrologists. Early referral in complex cases can improve outcomes and reduce the risk of irreversible renal damage.

Limitations of Antiproteinuric Therapy

Antiproteinuric therapy with ACE inhibitors and ARBs is not curative. These drugs reduce proteinuria and slow disease progression but do not reverse established glomerular damage. Some dogs will continue to progress to end-stage renal disease despite optimal medical management. The degree of proteinuria reduction correlates with renoprotective benefit, but individual responses vary widely. Dogs with amyloidosis or advanced glomerulosclerosis may have minimal antiproteinuric response.

Additionally, ACE inhibitors and ARBs can cause adverse effects, including azotemia, hyperkalemia, and hypotension, which may limit their use in some dogs. Close monitoring is essential to balance therapeutic benefit against potential harm. Owners should be counseled that management of nephrotic syndrome is a long-term commitment requiring regular veterinary visits, medication administration, and dietary compliance.

Practical Decision Framework for Antiproteinuric Therapy Titration and Monitoring in Canine Nephrotic Syndrome

Managing antiproteinuric therapy in dogs with nephrotic syndrome requires a structured, evidence-based approach that balances efficacy with renal safety. The following framework provides veterinarians with a stepwise protocol for initiating, titrating, and monitoring ACE inhibitor and angiotensin receptor blocker therapy, incorporating specific decision points, record-keeping requirements, and escalation criteria. This framework complements the general management principles described above by offering concrete operational guidance for daily clinical practice.

Initial Patient Assessment and Baseline Data Collection

Before initiating antiproteinuric therapy, a complete baseline assessment is essential. The minimum database should include serum creatinine, blood urea nitrogen, serum albumin, serum potassium, systolic blood pressure, and urine protein:creatinine ratio. The Merck Veterinary Manual emphasizes that accurate baseline values are critical for monitoring therapeutic response and detecting adverse effects. Baseline UPC should be measured on at least two separate occasions, ideally one to two weeks apart, to confirm persistent proteinuria and establish a reliable pretreatment value. If the UPC varies by more than 30% between measurements, a third sample should be obtained before starting therapy.

Volume status must be assessed clinically. Dogs with dehydration, hypovolemia, or concurrent diuretic therapy are at increased risk of acute kidney injury when ACE inhibitors are initiated. If the dog is receiving diuretics for edema management, the diuretic dose should be stabilized for at least three to five days before starting an ACE inhibitor. Serum creatinine should be stable or improving before initiating therapy. If the dog is azotemic, the underlying cause should be identified and addressed before starting an ACE inhibitor.

ACE Inhibitor Initiation Protocol

Benazepril and enalapril are the most commonly used ACE inhibitors in dogs with glomerular disease. An algorithm for administering ACE inhibitors and ARBs to treat proteinuria in dogs with glomerular disease provides a structured approach to dosing and monitoring. The starting dose for benazepril is 0.25 to 0.5 mg/kg orally every 24 hours. For enalapril, the starting dose is 0.25 to 0.5 mg/kg orally every 12 to 24 hours. Lower starting doses are recommended for dogs with baseline serum creatinine greater than 2.0 mg/dL or systolic blood pressure less than 120 mmHg.

The drug should be administered at the same time each day, with or without food. Owners should be instructed to observe for signs of weakness, lethargy, vomiting, or decreased appetite, which may indicate hypotension or azotemia. A medication log should be maintained, recording the date, dose, time of administration, and any observed adverse effects.

First Recheck Assessment: One to Two Weeks

The first recheck should occur seven to fourteen days after initiating therapy. This visit is critical for detecting acute adverse effects and establishing the initial therapeutic response. The following parameters should be measured:

• Serum creatinine and blood urea nitrogen
• Serum potassium
• Systolic blood pressure
• Urine protein:creatinine ratio
• Body weight
• Physical examination for edema or effusions

An acceptable response is defined as a UPC reduction of at least 25% from baseline without a significant increase in serum creatinine. A significant increase in serum creatinine is defined as a rise of more than 30% from baseline or an absolute value exceeding 2.5 mg/dL. If serum creatinine increases by more than 30%, the ACE inhibitor should be temporarily discontinued and volume status assessed. Once the dog is volume replete, the drug can be restarted at 50% of the original dose and rechecked again in seven days.

If serum potassium exceeds 5.5 mEq/L, the ACE inhibitor should be discontinued and serum potassium rechecked in three to five days. Persistent hyperkalemia may require dose reduction or switching to an ARB. If systolic blood pressure falls below 100 mmHg, the ACE inhibitor should be held until blood pressure normalizes, then restarted at a lower dose.

If the UPC reduction is less than 25% and serum creatinine is stable, the ACE inhibitor dose should be increased by 50% and the dog rechecked in another seven to fourteen days. This stepwise titration continues until the target UPC reduction is achieved or the maximum recommended dose is reached.

Titration Phase: Monthly Adjustments

For dogs with an acceptable initial response, the next recheck should occur at four weeks. The goal is to achieve a UPC reduction of at least 50% from baseline, with an ideal target UPC of less than 1.0. If the UPC has not decreased by at least 50%, the ACE inhibitor dose should be increased. The maximum recommended dose for benazepril is 0.5 to 1.0 mg/kg every 24 hours, and for enalapril is 0.5 mg/kg every 12 hours.

At each titration step, serum creatinine, potassium, and blood pressure must be reassessed. If the dog develops azotemia, hyperkalemia, or hypotension at any dose, the dose should be reduced to the previous tolerated level. If the maximum dose is reached without achieving a 50% UPC reduction, consider adding an angiotensin receptor blocker such as telmisartan. Telmisartan is dosed at 1 mg/kg orally every 24 hours and can be used in combination with an ACE inhibitor. The combination requires close monitoring for hyperkalemia and azotemia, with rechecks every two weeks during the first month of combination therapy.

Maintenance Phase: Long-Term Monitoring

Once a stable dose is established and the UPC target is achieved, rechecks should occur every one to three months. Each recheck should include serum creatinine, blood urea nitrogen, serum albumin, serum potassium, systolic blood pressure, UPC, body weight, and physical examination. The frequency of monitoring depends on disease stability. Dogs with stable UPC and renal function can be monitored every three months. Dogs with fluctuating parameters or those on combination therapy should be monitored monthly.

If the UPC increases by more than 50% from the previous value or exceeds 2.0, the following should be assessed:

• Owner compliance with medication administration
• Dietary compliance, particularly sodium and protein intake
• Blood pressure control
• Development of intercurrent illness or infection
• Progression of underlying glomerular disease

If no correctable cause is identified, the ACE inhibitor dose should be increased or an ARB added. If the dog is already on maximum therapy, referral for renal biopsy and consideration of immunosuppressive therapy is indicated.

Record System for Antiproteinuric Therapy

A standardized record system is essential for tracking therapeutic response and detecting trends over time. The following template can be used for each patient:

Each row represents a single visit. The notes column should document any adverse effects, dose changes, concurrent medications, or intercurrent illnesses. This record allows the clinician to visualize the trajectory of proteinuria and renal function over time and to identify patterns such as dose-dependent azotemia or seasonal fluctuations in UPC.

Troubleshooting Common Therapeutic Challenges

Several clinical scenarios require specific troubleshooting approaches.

Scenario One: Inadequate Initial Response

If the UPC does not decrease by at least 25% after two weeks of ACE inhibitor therapy at the starting dose, the most common causes are insufficient dosing, noncompliance, or concurrent hypertension. Blood pressure should be measured. If systolic pressure exceeds 160 mmHg, antihypertensive therapy should be intensified before increasing the ACE inhibitor dose. If blood pressure is controlled, the ACE inhibitor dose should be increased by 50% and the dog rechecked in two weeks. If the dog is already on the maximum dose, an ARB should be added.

Scenario Two: Azotemia with ACE Inhibitor Initiation

A rise in serum creatinine of 10% to 30% is common and acceptable, reflecting reduced glomerular capillary pressure. However, a rise of more than 30% requires intervention. The ACE inhibitor should be held, volume status assessed, and any dehydration corrected. Once volume replete, the drug should be restarted at 50% of the original dose. If azotemia recurs at the lower dose, the dog may have significant renal artery stenosis or advanced glomerulosclerosis, and ACE inhibitor therapy may not be tolerated. In such cases, consider ARB monotherapy at a low dose or referral to a specialist.

Scenario Three: Persistent Hyperkalemia

Hyperkalemia (serum potassium greater than 5.5 mEq/L) can occur with ACE inhibitor or ARB therapy, particularly in dogs with reduced renal function. Dietary potassium restriction should be reviewed. If the dog is on a potassium-sparing diuretic such as spironolactone, this should be discontinued. If hyperkalemia persists, the ACE inhibitor dose should be reduced or the drug switched to an ARB. If hyperkalemia is severe (greater than 6.0 mEq/L) or associated with cardiac arrhythmias, the drug should be discontinued and emergency treatment initiated.

Scenario Four: Hypotension

Symptomatic hypotension (systolic blood pressure less than 100 mmHg with weakness or lethargy) requires immediate dose reduction or discontinuation. Asymptomatic hypotension (systolic pressure 100 to 110 mmHg) may be tolerated if the dog is otherwise stable. If hypotension persists at the lowest effective dose, consider switching to an ARB, which may have less effect on systemic blood pressure.

Scenario Five: Breakthrough Proteinuria

A dog that was stable on ACE inhibitor therapy may develop increasing UPC over time. This breakthrough proteinuria may indicate progression of glomerular disease, development of hypertension, or noncompliance. Blood pressure should be measured and controlled. Dietary compliance should be verified. If no correctable cause is found, the ACE inhibitor dose should be increased or an ARB added. If the dog is already on maximum therapy, renal biopsy should be considered to guide further treatment.

Comparison of ACE Inhibitor and ARB Therapy

While ACE inhibitors are first-line therapy, ARBs such as telmisartan offer an alternative for dogs that do not tolerate ACE inhibitors or have an inadequate response. The following comparison aids clinical decision-making:

The choice between an ACE inhibitor and an ARB should be based on individual patient factors, including tolerance, cost, and availability. Some dogs may benefit from combination therapy, but this requires close monitoring.

Professional Escalation Criteria for Antiproteinuric Therapy

Veterinarians should consider referral to a veterinary internist or nephrologist in the following situations related to antiproteinuric therapy:

• Failure to achieve a 50% reduction in UPC after three months of maximum ACE inhibitor and ARB combination therapy
• Progressive azotemia (serum creatinine increasing by more than 0.5 mg/dL per month) despite optimal medical management
• Recurrent or severe hyperkalemia (serum potassium greater than 6.0 mEq/L) that cannot be managed with dose adjustment
• Symptomatic hypotension requiring drug discontinuation
• Development of thromboembolic complications while on prophylactic anticoagulation
• Need for renal biopsy to guide immunosuppressive therapy
• Suspected immune-mediated glomerulonephritis that may benefit from immunosuppression

The American College of Veterinary Internal Medicine provides resources for locating board-certified veterinary internists and nephrologists. Early referral in complex cases can improve outcomes and reduce the risk of irreversible renal damage.

Limitations of Antiproteinuric Therapy

Antiproteinuric therapy with ACE inhibitors and ARBs is not curative. These drugs reduce proteinuria and slow disease progression but do not reverse established glomerular damage. Some dogs will continue to progress to end-stage renal disease despite optimal medical management. The degree of proteinuria reduction correlates with renoprotective benefit, but individual responses vary widely. Dogs with amyloidosis or advanced glomerulosclerosis may have minimal antiproteinuric response.

Additionally, ACE inhibitors and ARBs can cause adverse effects, including azotemia, hyperkalemia, and hypotension, which may limit their use in some dogs. Close monitoring is essential to balance therapeutic benefit against potential harm. Owners should be counseled that management of nephrotic syndrome is a long-term commitment requiring regular veterinary visits, medication administration, and dietary compliance.

Frequently Asked Questions

What is the difference between nephrotic syndrome and glomerulonephritis in dogs?

Nephrotic syndrome is a clinical syndrome defined by proteinuria, hypoalbuminemia, and edema, which can result from various glomerular diseases. Glomerulonephritis is a specific histopathologic diagnosis of inflammation of the glomeruli, often immune-mediated. Not all dogs with glomerulonephritis develop nephrotic syndrome, and nephrotic syndrome can occur from non-inflammatory glomerular diseases such as amyloidosis.

How is proteinuria quantified in dogs with suspected nephrotic syndrome?

Proteinuria is quantified using the urine protein:creatinine ratio (UPC) on a voided or catheterized urine sample. A UPC greater than 2.0 is typical in nephrotic syndrome, but values can exceed 10.0. The UPC should be measured serially to monitor response to therapy. Prerenal and post-renal causes of proteinuria must be excluded before attributing proteinuria to glomerular disease.

When should a renal biopsy be performed in a dog with nephrotic syndrome?

Renal biopsy is indicated when the underlying cause of nephrotic syndrome is unclear, when immunosuppressive therapy is being considered, or when disease progression is rapid. Biopsy can differentiate between glomerulonephritis, amyloidosis, and other glomerular diseases. The procedure should be performed by a specialist using ultrasound guidance, with coagulation parameters assessed beforehand.

What is the role of ACE inhibitors in treating nephrotic syndrome in dogs?

ACE inhibitors such as benazepril and enalapril are first-line antiproteinuric therapy. They reduce proteinuria by decreasing glomerular capillary pressure and attenuating angiotensin II-mediated podocyte injury. An algorithm for administering ACE inhibitors and ARBs to treat proteinuria in dogs with glomerular disease provides a structured approach. ACE inhibitors should be started at a low dose and titrated based on UPC response and renal function.

Can immunosuppressive therapy cure nephrotic syndrome in dogs?

Immunosuppressive therapy can induce remission in some forms of immune-mediated glomerulonephritis, such as minimal change disease. However, response is variable, and many dogs require long-term therapy. Immunosuppression should only be initiated after renal biopsy confirmation of immune-mediated disease. A case report described combination of immunosuppressive drugs and allogeneic stem cell treatment in a dog with suspected nephrotic syndrome, but this is not standard therapy.

What dietary changes are recommended for dogs with nephrotic syndrome?

A renal protective diet is recommended, characterized by reduced protein content, restricted phosphorus, and low sodium. Omega-3 fatty acid supplementation may have anti-inflammatory and antiproteinuric effects. Commercial renal diets are available. Caloric intake should be adequate to maintain body weight. Dietary sodium restriction is the first step in managing edema.

How is thromboembolic risk assessed and managed in dogs with nephrotic syndrome?

Thromboembolic risk is assessed based on the degree of hypoalbuminemia and severity of proteinuria. Dogs with serum albumin less than 1.5 g/dL are at higher risk. Prophylactic anticoagulation with low-dose aspirin or clopidogrel may be considered. For dogs with confirmed thromboembolism, heparin followed by warfarin may be indicated, but this requires intensive monitoring and specialist consultation.

What is the prognosis for dogs with nephrotic syndrome?

Prognosis varies widely depending on the underlying glomerular disease and response to therapy. Dogs with minimal change disease or membranous glomerulonephritis may have a good prognosis with appropriate therapy. Dogs with amyloidosis generally have a poorer prognosis. Early diagnosis and aggressive management of proteinuria, hypertension, and thromboembolic risk can improve outcomes.

Related Veterinary Guides

• Dog
• Dog Shedding Management
• How To Skin A Dog
• Dog Kidney Disease Diet
• Arthritis In Dogs Symptoms And Diagnosis

References and Further Reading

• www.merckvetmanual.com
• www.aaha.org
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• Toceranib phosphate-associated nephrotic syndrome in a dog: a case report.. BMC veterinary research, 2021.
• Gluomerulonephritis and the nephrotic syndrome in a dog.. The Veterinary record, 1974.
• Combination of immunosuppressive drugs and allogeneic stem cell treatment in a dog with suspected nephrotic syndrome.. Veterinarni medicina, 2022.
• Amyloid nephrotic syndrome in the dog.. Journal of the American Veterinary Medical Association, 1969.
• Nephrotic syndrome resulting in thromboembolic disease and disseminated intravascular coagulation in a dog.. Journal of the American Animal Hospital Association, 1997.
• Proteinuria.. The American journal of medicine, 1974.
• Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children.. Journal of the American Society of Nephrology, 2017.
• Thromboembolic phenomena in patients with nephrotic syndrome: pathophysiology, risk factors, prophylaxis and treatment.. British journal of hospital medicine, 2024.
• Activation of TRPC6 by AngⅡ Induces Podocyte Injury and Participates in Proteinuria of Nephrotic Syndrome. Frontiers in Pharmacology, 2022.
• Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor. Journal of Comparative Pathology, 1997.
• An algorithm for administering ACE inhibitors and ARBs to treat proteinuria in dogs with glomerular disease. Veterinary Medicine, 2013.
• Plasma Concentrations of an Angiotensin-Converting Enzyme Inhibitor, Benazepril, and Its Active Metabolite, Benazeprilat, after Repeated Administrations of Benazepril in Dogs with Experimental Kidney Impairment. Journal of Veterinary Medical Science, 2000.
• Changes in renal function induced by ACE-inhibition in the conscious two-kidney, one-clip Goldblatt hypertensive dog. Nephron, 1992.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.